The Immunohistochemical Prognostic Value of Nuclear and Cytoplasmic Silent Information Regulator 1 Protein Expression in Saudi Patients with Breast Cancer by Bayan Alharbi, Alia Aldahlawi, Mourad Assidi, Fatemah Basingab, Kawther Zaher, Jehan Alrahimi, Sara Mokhtar, Jaudah Al-Maghrabi, Abdelbaset Buhmeida, Kaltoom Al-Sakkaf

“…Moreover, the cytoplasmic expression of SIRT1 in HER2-positive BC was associated with a larger tumor size (<i>p</i> = 0.036) and lymph node metastasis (<i>p</i> = 0.045). …”
Get full text

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre by Anna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, Soumaya Labidi, Victor Cohen, Lawrence Panasci, Jennifer E. Friedmann, François Patenaude, Cristiano Ferrario, Mark Basik, April A. N. Rose, Parvaneh Fallah

“…Of these, 15 patients had classically defined HER2-positive (HER2+) breast cancer, 4 of whom had active central nervous system (CNS) metastases. …”
Get full text

Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence by Ji‐Hua Shi, Wen‐Zhi Guo, Yang Jin, Hua-Peng Zhang, Chun Pang, Jie Li, Pål‐Dag Line, Shui‐Jun Zhang

“…Trastuzumab with the high concentrations suppressed proliferation of HER2‐positive hepatoma cells (P < 0.05); in the coculture model to induce EMT of JM1 cells, HER2 expression increased with downregulated E‐cadherin and upregulated Vimentin. …”
Get full text

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer by Jonathan Henricks, Tyler Haddad, Omair Ahmed, Jonathan Schoenhals, Pavnesh Kumar, Ryan Wilson, Jianing Ma, Jing Gennie Wang, Michael Wert, Vincent Esguerra, Ian Bentley, Kai Johnson, Daniel Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Kevin Ho

“…Abstract Background Trastuzumab deruxtecan (T-DXd) is FDA-approved for treatment of patients with HER2 positive and HER2-low metastatic breast cancer. …”
Get full text

Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo by Zheng Wang, Yu Liu, Yunxia Xu, Lin Lu, Zhen Zhu, Baojie Lv, Xin Fang, Yao Tang, Jinhua Wang, Yu Cheng, Ying Hu, Junwen Lou, Peican Wu, Chendan Liu, Yanjun Liu, Xin Zeng, Qing Xu

“…Among them, biparatopic antibodies (bpAbs) have shown improved efficacy compared to monoclonal antibody (mAb) combinations in HER2-positive patients. BpAbs bind two independent epitopes on the same antigen, which allows fine-tuning of mechanisms of action, including enhancement of on-target specificity and induction of strong antigen clustering due to the unique binding mode. …”
Get full text

Describing quality of life trajectories in young Hispanic women with breast cancer: 5-year results from a large prospective cohort by Bryan F. Vaca-Cartagena, Ana S. Ferrigno Guajardo, Hatem A. Azim Jr, Federico Rotolo, Antonio Olivas-Martinez, Alejandra Platas, Alan Fonseca, Fernanda Mesa-Chavez, Marlid Cruz-Ramos, Ana Rodriguez, Alejandro Mohar, Cynthia Villarreal-Garza

“…Regular alcohol consumption at diagnosis (aOR [adjusted odds ratio] 1.64; 95 % CI [confidence interval] 1.02–2.65) and HER2-positive BC (aOR 2.53; 95 % CI 1.35–4.73) were independent factors associated with classification to the poor and good groups, respectively. …”
Get full text

Unveiling the prognostic value of ARID3A in breast cancer through bioinformatic analysis by Wen-Run Cai, Xu-Gang Sun, Yue Yu, Xin Wang, Xu-Chen Cao, Xiao-Feng Liu

“…Results: Elevated ARID3A expression was associated with poor prognosis in breast cancer, particularly in Luminal and HER2-positive subtypes. A positive correlation with REXO1 was identified, and enrichment analysis emphasized ARID3A's involvement in immune-related pathways, such as “interferon gamma production” and “primary immunodeficiency.” …”
Get full text

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients by Matthew G. Hanna, Ira J. Bleiweiss, Anupma Nayak, Shabnam Jaffer

“…Increasing RR was inversely related to PR positivity but directly to Her2 positivity. Of the morphologic parameters, a tubular(lobular) morphology correlated only with low-intermediate scores and anaplastic type with intermediate-high scores. …”
Get full text